Fareston Related Published Studies
Well-designed clinical trials related to Fareston (Toremifene)
Prostate cancer diagnosis among men with isolated high-grade intraepithelial
neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral
toremifene. [2013]
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy
for prostate cancer. [2013]
Toremifene decreases vertebral fractures in men younger than 80 years receiving
androgen deprivation therapy for prostate cancer. [2011]
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. [2010.10]
Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial. [2010.07]
Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. [2010.05.15]
Cardiovascular safety of degarelix: results from a 12-month, comparative,
randomized, open label, parallel group phase III trial in patients with prostate
cancer. [2010]
Breast magnetic resonance imaging findings in women treated with toremifene for premenstrual mastalgia. [2009.11]
Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. [2008.04.10]
Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. [2008.01]
Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. [2007.11.01]
Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. [2006.09]
Toremifene for premenstrual mastalgia: a randomised, placebo-controlled crossover study. [2006.06]
Bone mineral density and lipid changes during 5 years of follow-up in a study of prevention of breast cancer with toremifene in healthy, high-risk pre- and post-menopausal women. [2005.10]
Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. [2004.12]
Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer. [2004.11]
[Activity of toremifene plus mitomycin, vindesin and cisplatin regimen in unresectable non-small cell lung cancer] [2004.08]
Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene. [2004.07.15]
Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. [2003.10]
Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia. [2003.06]
Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women. [2001.04.06]
Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer. [2001.01]
Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. [2000.10.15]
Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. [2000.10]
Antiestrogenic tamoxifen and toremifene increase serum leptin levels in postmenopausal breast cancer patients. [2000.05.29]
Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients. [2000]
Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer. [1999.11]
Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. [1998.12]
Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. [1998.04]
A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group. [1997.09]
Evolving role of toremifene in the adjuvant setting. [1997.05]
High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer. [1997.05]
Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study. [1997]
Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. [1996.02]
Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer. [1995.12]
Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. [1995.11]
Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. [1995.10]
Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women. [1993.04]
Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial. [1993]
Phase I study of toremifene in patients with advanced cancer. [1991.11]
Phase III studies of toremifene in metastatic breast cancer. [1990.08]
Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer. [1990.08]
Hormonal effects of toremifene in breast cancer patients. [1990.06.22]
Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. [1990]
Well-designed clinical trials possibly related to Fareston (Toremifene)
Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. [2011.08]
Factors associated with vertebral fractures in men treated with androgen
deprivation therapy for prostate cancer. [2011]
Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group. [2009.03]
Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. [2008.09.10]
Body mass index influences palpability but not stage of breast cancer at diagnosis. [2007.06]
Adverse outcome and resistance to adjuvant antiestrogen therapy in node-positive postmenopausal breast cancer patients-The role of p53. [2006.02]
A double-blind randomized controlled trial of toremifen therapy for mastalgia. [2006.01]
Drug resistance in chemotherapy for breast cancer. [2005.11]
Urogenital effects of selective estrogen receptor modulators: a systematic review. [2005.09]
The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. [2001.04.20]
Antiestrogens reduce plasma levels of endothelin-1 without affecting nitrate levels in breast cancer patients. [2000.02]
[Results of phase II clinical trial of Tamoxifen and Toremifen in two different doses in advanced breast cancer in postmenopausal women] [1997]
Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. [1997]
Other research related to Fareston (Toremifene)
Toremifene and tamoxifen have similar efficacy in the treatment of patients with
breast cancer: a meta-analysis of randomized trials. [2014]
Phase III randomized trial of toremifene versus tamoxifen for Japanese
postmenopausal patients with early breast cancer. [2014]
Toremifene versus tamoxifen for advanced breast cancer. [2012]
Pharmacokinetic evaluation of toremifene and its clinical implications for the
treatment of osteoporosis. [2012]
Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer: the results of a 2-year multicenter open randomized study. [2011.08]
Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials. [2011.08]
[A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer]. [2011.07]
Diethylenetriamine pentaacetic acid derivative of toremifene and in vitro evaluation in human breast cancer cell line MCF-7. [2011.02]
[A case of aromatase inhibitor-tolerant metastatic breast cancer revealing complete remission with high-dose toremifene therapy]. [2011.01]
Effects of toremifene and anastrozole on serum lipids and bone metabolism in
postmenopausal females with estrogen receptor-positive breast cancer: the results
of a 2-year multicenter open randomized study. [2011]
[The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer]. [2010.11]
Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor. [2010.10]
Uterine changes during tamoxifen, toremifene, and other therapy for breast cancer: evaluation with magnetic resonance imaging. [2010.07]
[Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients] [2010.02]
Toremifene use does not alter serum inhibin A and B levels during mid-luteal phase in women with premenstrual mastalgia. [2010.02]
Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients
with early breast cancer: interim results from a Japanese phase III trial. [2010]
Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast
cancer. [2010]
[A case of advanced breast cancer with multiple bone metastases responding to docetaxel and high-dose toremifene as fourth-line chemo-endocrine therapy] [2009.12]
[A case of advanced breast cancer with skin ulceration successfully treated with paclitaxel and toremifene therapy] [2009.11]
[Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors] [2009.09]
Breast Magnetic Resonance Imaging Findings in Women Treated with Toremifene for Premenstrual Mastalgia. [2009.08.27]
Efficacy and tolerability of weekly paclitaxel in combination with high-dose toremifene citrate in patients with metastatic breast cancer. [2009.08]
[Efficacy of treatment with high-dose toremifene in patients with metastatic breast cancer resistant to aromatase inhibitor treatment] [2009.06]
[A case of metastatic breast cancer resistant to anastrozole treatment responding to high-dose toremifene] [2009.04]
Comparing the effects of atamestane, toremifene and tamoxifen alone and in combination, on bone, serum lipids and uterus in ovariectomized rats. [2009.02]
Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer. [2009]
[Recurrence of skin and lymph nodes from asynchronous breast cancer successfully treated with paclitaxel and toremifene therapy--a case report] [2008.11]
Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model. [2008.01]
The beneficial effects of toremifene administration on the hypothalamic-pituitary-testicular axis and sperm parameters in men with idiopathic oligozoospermia. [2007.10]
[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy] [2007.07]
The effects of atamestane and toremifene alone and in combination compared with letrozole on bone, serum lipids and the uterus in an ovariectomized rat model. [2007.07]
The beneficial effects of toremifene administration on the hypothalamic-pituitary-testicular axis and sperm parameters in men with idiopathic oligozoospermia. [2007.04.03]
[A case of advanced breast cancer with multiple liver metastases resistant to chemotherapy responding to high-dose toremifene] [2007.03]
[A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine] [2007.03]
DNA adduct formation in the livers of female Sprague-Dawley rats treated with toremifene or alpha-hydroxytoremifene. [2007.02]
DNA adduct formation in the livers of female Sprague-Dawley rats treated with toremifene or alpha-hydroxytoremifene. [2007.02]
[A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel] [2007.01]
Toremifene: an evaluation of its safety profile. [2006.04]
Absence of DNA adduct in the leukocytes from breast cancer patients treated with toremifene. [2006.03]
Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. [2006.03]
[Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer] [2005.10]
Stabilization and regression of a recurrent desmoid tumor with the antiestrogen toremifene. [2005.08]
A highly vascular intracranial solitary fibrous tumor treated with radiotherapy and toremifene: case report. [2005.06]
Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene. [2005.04]
|